 Jonathan Port
Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA-Binding Proteins | 8 | 2010 | 369 | 1.300 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein D | 5 | 2010 | 9 | 1.230 |
Why?
| | Antigens, Surface | 5 | 2010 | 156 | 1.220 |
Why?
| | RNA, Messenger | 12 | 2015 | 2657 | 1.100 |
Why?
| | Receptors, Adrenergic, beta | 8 | 2004 | 142 | 1.070 |
Why?
| | MicroRNAs | 5 | 2015 | 633 | 0.780 |
Why?
| | Receptors, Adrenergic, beta-1 | 8 | 2015 | 53 | 0.610 |
Why?
| | RNA Stability | 3 | 2004 | 97 | 0.590 |
Why?
| | Myocardium | 10 | 2011 | 965 | 0.570 |
Why?
| | Adrenergic beta-Antagonists | 6 | 2015 | 301 | 0.470 |
Why?
| | Cardiomyopathy, Dilated | 5 | 2015 | 344 | 0.440 |
Why?
| | 3' Untranslated Regions | 4 | 2010 | 141 | 0.390 |
Why?
| | Poly(A)-Binding Proteins | 1 | 2010 | 5 | 0.390 |
Why?
| | Fluorescence Resonance Energy Transfer | 2 | 2010 | 178 | 0.360 |
Why?
| | Propanolamines | 4 | 2013 | 93 | 0.340 |
Why?
| | Multiprotein Complexes | 1 | 2010 | 148 | 0.340 |
Why?
| | Cricetinae | 5 | 2010 | 261 | 0.320 |
Why?
| | ELAV Proteins | 5 | 2010 | 17 | 0.320 |
Why?
| | ELAV-Like Protein 1 | 5 | 2010 | 20 | 0.320 |
Why?
| | Gene Expression Regulation | 5 | 2011 | 2435 | 0.310 |
Why?
| | Protein Interaction Mapping | 1 | 2007 | 104 | 0.290 |
Why?
| | Myocardial Ischemia | 1 | 2008 | 251 | 0.280 |
Why?
| | Polymorphism, Genetic | 4 | 2013 | 641 | 0.280 |
Why?
| | Heart Failure | 9 | 2013 | 1967 | 0.250 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 2 | 2004 | 9 | 0.250 |
Why?
| | Anisomycin | 1 | 2004 | 5 | 0.250 |
Why?
| | Signal Transduction | 9 | 2011 | 4688 | 0.240 |
Why?
| | Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 18 | 0.240 |
Why?
| | Myocardial Infarction | 1 | 2011 | 967 | 0.240 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2004 | 116 | 0.230 |
Why?
| | Globins | 1 | 2002 | 22 | 0.210 |
Why?
| | Enzyme Activation | 1 | 2004 | 810 | 0.210 |
Why?
| | Animals | 16 | 2011 | 33152 | 0.200 |
Why?
| | Cell Line | 5 | 2010 | 2693 | 0.190 |
Why?
| | Protein Binding | 5 | 2010 | 1969 | 0.190 |
Why?
| | Down-Regulation | 3 | 2015 | 623 | 0.190 |
Why?
| | Receptors, Adrenergic | 1 | 2000 | 36 | 0.180 |
Why?
| | Heart Ventricles | 3 | 2015 | 725 | 0.170 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 1795 | 0.170 |
Why?
| | Carbazoles | 2 | 2001 | 80 | 0.150 |
Why?
| | Models, Biological | 2 | 2001 | 1701 | 0.150 |
Why?
| | Gene Expression Profiling | 4 | 2015 | 1590 | 0.140 |
Why?
| | Heterogeneous-Nuclear Ribonucleoproteins | 2 | 2004 | 19 | 0.110 |
Why?
| | Base Sequence | 4 | 2002 | 2148 | 0.110 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1992 | 32 | 0.100 |
Why?
| | Recombinant Proteins | 3 | 2002 | 1302 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2004 | 2216 | 0.100 |
Why?
| | Protein Transport | 2 | 2010 | 407 | 0.100 |
Why?
| | Half-Life | 2 | 2002 | 147 | 0.090 |
Why?
| | Software | 1 | 2015 | 566 | 0.090 |
Why?
| | Mice | 6 | 2011 | 15446 | 0.090 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2009 | 17 | 0.090 |
Why?
| | Vasodilator Agents | 1 | 1992 | 328 | 0.090 |
Why?
| | Adrenergic beta-Agonists | 2 | 2001 | 130 | 0.090 |
Why?
| | Protein Multimerization | 1 | 2010 | 161 | 0.090 |
Why?
| | Gene Expression | 1 | 2015 | 1482 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2011 | 2012 | 0.090 |
Why?
| | Atrial Fibrillation | 1 | 2013 | 338 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 980 | 0.080 |
Why?
| | Norepinephrine | 1 | 2009 | 212 | 0.080 |
Why?
| | Heart Function Tests | 1 | 2008 | 61 | 0.080 |
Why?
| | Antihypertensive Agents | 1 | 1992 | 436 | 0.080 |
Why?
| | Transfection | 2 | 2002 | 887 | 0.080 |
Why?
| | Humans | 19 | 2015 | 118270 | 0.080 |
Why?
| | Molecular Sequence Data | 4 | 2007 | 2855 | 0.080 |
Why?
| | Phenotype | 1 | 2015 | 2937 | 0.070 |
Why?
| | Cytoplasm | 1 | 2007 | 269 | 0.070 |
Why?
| | Ultraviolet Rays | 2 | 2002 | 381 | 0.070 |
Why?
| | Animals, Newborn | 1 | 2008 | 804 | 0.070 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2007 | 159 | 0.070 |
Why?
| | GTP-Binding Proteins | 2 | 1996 | 147 | 0.070 |
Why?
| | Ventricular Function, Left | 1 | 2008 | 468 | 0.060 |
Why?
| | Biological Products | 1 | 2007 | 170 | 0.060 |
Why?
| | Heterogeneous Nuclear Ribonucleoprotein A1 | 2 | 2004 | 6 | 0.060 |
Why?
| | DNA Primers | 3 | 2011 | 532 | 0.060 |
Why?
| | Butadienes | 1 | 2004 | 33 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2007 | 577 | 0.060 |
Why?
| | Anthracenes | 1 | 2004 | 29 | 0.060 |
Why?
| | Flavonoids | 1 | 2004 | 69 | 0.060 |
Why?
| | RNA Precursors | 1 | 2004 | 136 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 964 | 0.060 |
Why?
| | Nitriles | 1 | 2004 | 155 | 0.060 |
Why?
| | RNA Splicing | 1 | 2004 | 242 | 0.060 |
Why?
| | Imidazoles | 1 | 2004 | 227 | 0.050 |
Why?
| | Rats | 2 | 2008 | 5339 | 0.050 |
Why?
| | Base Composition | 1 | 2002 | 77 | 0.050 |
Why?
| | Regulatory Sequences, Ribonucleic Acid | 1 | 2002 | 18 | 0.050 |
Why?
| | Uracil | 1 | 2002 | 35 | 0.050 |
Why?
| | Xamoterol | 1 | 2001 | 2 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 341 | 0.050 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2002 | 75 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2007 | 808 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 4887 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2004 | 1202 | 0.050 |
Why?
| | Hypertrophy | 1 | 2001 | 121 | 0.050 |
Why?
| | Male | 10 | 2015 | 57479 | 0.050 |
Why?
| | Isoproterenol | 2 | 1998 | 123 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2007 | 2063 | 0.050 |
Why?
| | Pyridines | 1 | 2004 | 436 | 0.050 |
Why?
| | Adenine | 1 | 2002 | 222 | 0.050 |
Why?
| | Precipitin Tests | 1 | 2000 | 94 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 817 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2008 | 4044 | 0.050 |
Why?
| | Chromatography, Affinity | 1 | 2000 | 86 | 0.050 |
Why?
| | Ribonucleoproteins | 1 | 2000 | 88 | 0.040 |
Why?
| | Computational Biology | 2 | 2015 | 541 | 0.040 |
Why?
| | Cycloheximide | 1 | 1998 | 55 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1998 | 45 | 0.040 |
Why?
| | Adenylyl Cyclases | 2 | 1995 | 86 | 0.040 |
Why?
| | Drug Stability | 1 | 1998 | 153 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2000 | 871 | 0.040 |
Why?
| | Receptors, Angiotensin | 1 | 1997 | 10 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 1998 | 395 | 0.040 |
Why?
| | Mass Spectrometry | 1 | 2000 | 670 | 0.040 |
Why?
| | Polyribosomes | 1 | 1996 | 23 | 0.040 |
Why?
| | Age Factors | 2 | 2015 | 2990 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2000 | 1681 | 0.030 |
Why?
| | Brain Death | 1 | 1995 | 28 | 0.030 |
Why?
| | Catecholamines | 1 | 1995 | 100 | 0.030 |
Why?
| | Muscle, Smooth | 1 | 1996 | 157 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 83 | 0.030 |
Why?
| | Computer Graphics | 1 | 2015 | 47 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 1995 | 338 | 0.030 |
Why?
| | Echocardiography | 2 | 2011 | 556 | 0.030 |
Why?
| | Data Interpretation, Statistical | 1 | 2015 | 334 | 0.030 |
Why?
| | Iodocyanopindolol | 1 | 1992 | 12 | 0.030 |
Why?
| | Pindolol | 1 | 1992 | 16 | 0.030 |
Why?
| | Culture Techniques | 1 | 1992 | 81 | 0.030 |
Why?
| | Stroke Volume | 1 | 2015 | 513 | 0.030 |
Why?
| | Ventricular Dysfunction, Left | 1 | 1995 | 374 | 0.030 |
Why?
| | Models, Genetic | 1 | 2015 | 592 | 0.030 |
Why?
| | Binding, Competitive | 1 | 1992 | 204 | 0.030 |
Why?
| | Chronic Disease | 1 | 1998 | 1631 | 0.030 |
Why?
| | Apoptosis | 1 | 2001 | 2461 | 0.030 |
Why?
| | Time Factors | 1 | 2002 | 6368 | 0.020 |
Why?
| | Female | 7 | 2015 | 61269 | 0.020 |
Why?
| | Cyclic AMP | 1 | 1992 | 240 | 0.020 |
Why?
| | Precision Medicine | 1 | 2015 | 354 | 0.020 |
Why?
| | Heart Transplantation | 2 | 1993 | 672 | 0.020 |
Why?
| | Glycine | 1 | 2011 | 162 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2011 | 333 | 0.020 |
Why?
| | Up-Regulation | 1 | 1993 | 862 | 0.020 |
Why?
| | Arginine | 1 | 2011 | 247 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1765 | 0.020 |
Why?
| | Lymphocytes | 1 | 1992 | 346 | 0.020 |
Why?
| | Heart | 1 | 1993 | 630 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 764 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1288 | 0.020 |
Why?
| | Spodoptera | 1 | 2007 | 37 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1522 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 2057 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2007 | 369 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2007 | 396 | 0.020 |
Why?
| | Middle Aged | 3 | 2015 | 27514 | 0.020 |
Why?
| | Receptors, Adrenergic, beta-2 | 2 | 1997 | 44 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2007 | 822 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2004 | 32 | 0.020 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2004 | 20 | 0.020 |
Why?
| | Hyaluronan Receptors | 1 | 2004 | 92 | 0.020 |
Why?
| | Aged | 2 | 2015 | 19599 | 0.020 |
Why?
| | Hyperplasia | 1 | 2004 | 170 | 0.020 |
Why?
| | Reference Values | 2 | 1997 | 770 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2004 | 345 | 0.010 |
Why?
| | Alternative Splicing | 1 | 2004 | 190 | 0.010 |
Why?
| | Phosphorylation | 1 | 2007 | 1622 | 0.010 |
Why?
| | Hippocampus | 1 | 2007 | 735 | 0.010 |
Why?
| | Models, Molecular | 1 | 2007 | 1434 | 0.010 |
Why?
| | Polymerase Chain Reaction | 2 | 1997 | 1004 | 0.010 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2004 | 317 | 0.010 |
Why?
| | Infant | 1 | 2015 | 8254 | 0.010 |
Why?
| | Peptides | 1 | 2007 | 879 | 0.010 |
Why?
| | Prospective Studies | 1 | 2013 | 6443 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 9448 | 0.010 |
Why?
| | Islets of Langerhans | 1 | 2007 | 739 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1221 | 0.010 |
Why?
| | Young Adult | 1 | 2015 | 10731 | 0.010 |
Why?
| | Adult | 3 | 2015 | 31328 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 9319 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2009 | 6541 | 0.010 |
Why?
| | Insulin | 1 | 2007 | 2157 | 0.010 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 1997 | 8 | 0.010 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 1997 | 22 | 0.010 |
Why?
| | Radioligand Assay | 1 | 1997 | 45 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2004 | 2262 | 0.010 |
Why?
| | Adolescent | 1 | 2015 | 18364 | 0.010 |
Why?
| | Angiotensin II | 1 | 1997 | 107 | 0.010 |
Why?
| | Child | 1 | 2015 | 19033 | 0.010 |
Why?
| | Antisense Elements (Genetics) | 1 | 1993 | 5 | 0.010 |
Why?
| | Heart-Lung Transplantation | 1 | 1993 | 11 | 0.010 |
Why?
| | Denervation | 1 | 1993 | 20 | 0.010 |
Why?
| | Kinetics | 1 | 1997 | 1623 | 0.010 |
Why?
| | Tissue Donors | 1 | 1995 | 334 | 0.010 |
Why?
| | Cell Membrane | 1 | 1997 | 700 | 0.010 |
Why?
| | Reoperation | 1 | 1993 | 557 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1995 | 3156 | 0.000 |
Why?
| | DNA | 1 | 1993 | 1385 | 0.000 |
Why?
|
|
Port's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|